Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases

• T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalities
• Cizutamig (BCMA TCE) positioned as first and best-in-class for autoimmune diseases
• Over 60 patients with autoimmune diseases dosed with cizutamig and CND261 (CD20 TCE) bringing total clinical experience inclusive of oncology to nearly 200 patients

Excerpt from the Press Release:

SAN DIEGO–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced continued clinical progress with cizutamig (BCMA TCE) and CND261 (CD20 TCE). Clinical evaluation is ongoing under multiple active INDs, investigator-initiated trials and compassionate use across ten clinical indications.

“In 2024, we started Candid with a hypothesis that TCEs could work similarly to cell therapy in autoimmune diseases. In 2025, clinical proof-of-concept for TCEs in autoimmune diseases was established,” said Dr. Ken Song, Chairman, President and CEO of Candid. “As we enter 2026, our focus is on a development strategy to maximize the commercial potential of TCEs and further establish Candid as the industry leading TCE company for autoimmune diseases.”

Cizutamig (BCMA TCE) has been administered in 80 patients, with half treated for autoimmune diseases. In autoimmune patients, cizutamig has demonstrated:

• On-target pharmacology with deep B-cell and plasma cell depletion in tissues
• Promising clinical efficacy in multiple autoimmune diseases including patients who have failed treatment with rituximab (anti-CD20 monoclonal antibody), efgartigimod (anti-FcRn), complement inhibitors, and other standard of care drugs

Click the button below to read the entire Press Release:

Continue Reading The Press Release